In Vitro & In Vivo Diagnostic Substances · DE · CIK 899923
Myriad Genetics develops and commercializes molecular tests for genetic insights to guide disease risk assessment and treatment decisions
Comparable business profile · signals at a glance
In the 90 days to Mar 9, 2026: 2 insiders bought $695K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 | Raha Samraat S.President and CEO | Buy | 40,000 | $5.00 | $200K |
| Feb 27, 2026 | Phanstiel S. LouiseDirector | Buy | 48,000 | $4.66 | $224K |
| Feb 26, 2026 | Phanstiel S. LouiseDirector | Buy | 50,407 | $4.80 | $242K |
| Feb 25, 2026 | Phanstiel S. LouiseDirector | Buy | 6,100 | $4.74 | $29K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.